Capricor announces that individuals with Duchenne treated with deramiocel had significantly less progression in loss of upper limb function

Capricor announces that individuals with Duchenne treated with deramiocel had significantly less progression in loss of upper limb function

Capricor Therapeutics received early funding from CureDuchenne, and today Capricor released new data reporting that individuals treated with deramiocel over three years experienced an average decline in Performance of the Upper Limb (PUL 2.0) total score of 3.46 points, compared to a 7.19-point decline in the external comparator group (p=0.019). Capricor reports that this equates to a 52% slowing of disease progression.  Capricor’s Biologics Lic…

The Community of Madrid has achieved an important advance in the therapy against muscular dystrophy of Duchenne, a degenerative disease that does not yet have a cure.... The entry Madrid researchers achieve an important advance in the therapy with nanoparticles for muscular dystrophy of Duchenne was first published in Gazetín Madrid.